Specialty Pharmacy

In a Pharmacy Times Continuing Education Supplement, Elena E. Perez, MD, PhD, examined the evolution of immunoglobulin [Ig] in its treatment use, including patient populations and potential adverse events.

Patients with diabetes demonstrated a higher likelihood of developing non-Hodgkin lymphoma than those without diabetes, especially among men.

Top news of the day across the health care landscape.

Specialty pharmacies are uniquely positioned to assist prescribers in managing patient care and offsetting administrative burden.

Obesity-associated cancer burden is shifting toward younger individuals, with more dramatic increases in some populations than others.

Top news of the day from across the health care landscape.

Top news of the day across the health care landscape.

Transplanting organ from patients infected with hepatitis C could greatly expand the number of kidneys available and reduce wait times.

New approach involves treating patients with a high dose factor VIII concentrates along with emicizumab, a modification of the standard immune tolerance induction.

Top news of the day from across the health care landscape.

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.

The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.

Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.

Research demonstrates a new direction in cell signaling and treatment for chronic inflammatory diseases such as psoriasis, asthma, and HIV.

The annual National Association of Specialty Pharmacy annual meeting shed light on the significant role these caregivers play in patient care.

The significant jump in hospital-owned specialty pharmacies bolsters the belief that health system leaders increasingly understand how these services enable their organizations to enhance patient care and achieve market differentiation.

Top news of the week from Specialty Pharmacy Times.

Study finds association between obesity and a greater burden of symptoms and distress among patients with breast or prostate cancer.

Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer.

New updates to immunization guidelines in multiple sclerosis outline recommendations on vaccination decisions for patients.

Dietary interventions that raise levels of high-density lipoprotein, or good cholesterol, may affect fatigue symptoms in multiple sclerosis.

An autopsy-based study examined long-term trends in HIV-related mortality among individuals living with the disease in New York City.

Results from a phase 2 study demonstrated complete tumor responses in patients with metastatic renal cell carcinoma treated with the combination lixadencel and sunitinib.

Novel combination may improve efficacy of immune checkpoint inhibitors in treating non-small cell lung cancer.

Nintedanib (Ofev, Boehringer Ingelheim) is now the first therapy approved for patients with interstitial lung disease associated with systemic sclerosis.

Two separate studies highlighted how high drug costs and requirements for prior authorization can hinder access to cancer treatment and affect outcomes.

Anifrolumab (AstraZeneca) demonstrated a statistically significant and clinically meaningful reduction in disease activity based on composite lupus assessment.